New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
16:12 EDTMDVN, MRKMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
News For MDVN;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
08:35 EDTMDVNMedivation price target raised to $166 at William Blair after talazoparib deal
Subscribe for More Information
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
August 24, 2015
07:02 EDTMDVNMedivation to acquire worldwide rights to Talazoparib from BioMarin
Medivation (MDVN) and BioMarin Pharmaceutical (BMRN) have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib, a highly-potent, orally-available poly ADP ribose polymerase inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. Under the agreement, Medivation will be responsible for all research, development, regulatory and commercialization activities for all indications on a global basis. Under the terms of the agreement, Medivation will pay BioMarin $410 million upfront, up to an additional $160 million upon the achievement of regulatory and sales-based milestones and mid-single digit royalties for talazoparib. At the closing of the transaction, Medivation will assume all financial obligations associated with the development and commercialization of talazoparib. The closing of the transaction is conditioned on the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is anticipated to close in 2015.
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information
August 13, 2015
10:55 EDTMRKBMO upgrades Merck on Alzheimer's, lung cancer drug prospects
Subscribe for More Information
10:00 EDTMRKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A. Schulman (SHLM) upgraded to Buy from Accumulate at Global Hunter... American Capital Agency (AGNC) upgraded to Buy from Neutral at Compass Point... Annaly Capital (NLY) upgraded to Buy from Neutral at Compass Point... Aramark (ARMK) upgraded to Outperform at Baird... Bernstein upgrades Yahoo (YHOO), says shares pricing in 'almost' worst case scenario... BreitBurn Energy (BBEP) upgraded to Neutral from Sell at UBS... CAE (CAE) upgraded to Buy from Hold at Desjardins... Capital One (COF) upgraded at Argus... Coca-Cola Enterprises (CCE) upgraded to Outperform from Underperform at CLSA... Community Health (CYH) upgraded to Outperform from Market Perform at Raymond James... EZchip (EZCH) upgraded to Buy from Hold at Brean Capital... Enzymotec (ENZY) upgraded to Outperform from Market Perform at Wells Fargo... Extra Space Storage (EXR) upgraded on positive catalysts at BMO Capital... Green Plains (GPRE) upgraded to Buy from Neutral at Goldman... Legg Mason (LM) upgraded to Overweight from Equal Weight at Barclays... Lincoln National (LNC) upgraded to Overweight at Morgan Stanley... Merck (MRK) upgraded on improved pipeline outlook at BMO Capital... Microsoft (MSFT) upgraded to Buy from Hold at Stifel... Monster Beverage (MNST) upgraded to Overweight from Equal Weight at Morgan Stanley... National Research (NRCIB) upgraded to Overweight from Equal-Weight at First Analysis... Qlik Technologies (QLIK) upgraded to Buy from Hold at Deutsche Bank... Spectra Energy Partners (SEP) upgraded to Overweight from Neutral at JPMorgan... Yahoo (YHOO) upgraded to Outperform from Market Perform at Bernstein.
08:33 EDTMRKMerck upgraded on improved pipeline outlook at BMO Capital
As noted earlier, BMO Capital upgraded Merck to Outperform from Market Perform. The firm has become more upbeat on the company's pipeline and predicts that upcoming data wil raise the Street's expectations for the company, leading to multiple expansion. The firm is impressed with the company's recent commercial execution and is upbeat on the company's near-term and long-term outlook. Target to $70 from $65.
08:01 EDTMRKMerck, MD Anderon Cancer Center partner to evaluate Keytruda treatment
Subscribe for More Information
06:29 EDTMRKMerck upgraded to Outperform from Market Perform at BMO Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use